CureVac’s Covid vaccine is more effective, but may not be enough

CureVac NV, headquartered in Germany with a U.S. office in Boston, on Wednesday released midstage trial data showing that its Covid-19 vaccine candidate is 48% effective against "any severity" of the disease.